MIM
ELEV

MetLife Investment Management’s Elevation Oncology ELEV Stock Holding History

MetLife Investment Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,465
Closed -$39.1K – 2863
2024
Q2 		$39.1K Buy
+14,465
New +$54.5K ﹤0.01% 2797

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

MetLife Investment Management's ELEV Position: Q3 2024 in Review

MetLife Investment Management sold out of Elevation Oncology (ELEV) in Q3 2024, closing a stake of 14,465 shares — an estimated $39.1K sold.

MetLife Investment Management first reported a position in ELEV in Q2 2024 and held it in 1 quarter. The position peaked at $39.1K in Q2 2024. 68 funds tracked by Wall St. Rank hold ELEV as of Q3 2024.

  • MetLife Investment Management reported no remaining Elevation Oncology position as of Q3 2024 after selling out during the quarter.
  • MetLife Investment Management sold 14,465 Elevation Oncology shares in Q3 2024, an estimated $39.1K.
  • MetLife Investment Management first reported a position in Elevation Oncology in Q2 2024 and held it in 1 quarter.
  • MetLife Investment Management's Elevation Oncology position peaked at $39.1K in Q2 2024.
  • 68 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.